US Senator Asks NIH's Collins to License Out Myriad's BRCA 1/2 Gene Patents | GenomeWeb

NEW YORK (GenomeWeb News) – The chairman of the US Senate Judiciary Committee has asked National Institutes of Health Director Francis Collins to invoke a provision in federal law, which has never been used before, to license out Myriad Genetic's BRCA 1 and BRCA 2 gene patents.

Sen. Patrick Leahy (D-Vt.) last week sent a letter to Collins asking him to consider use of the so-called march-in rights under the Bayh-Dole Act "to ensure greater access to genetic testing for breast and ovarian cancer."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.